Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
22.72
+0.89 (4.08%)
At close: Feb 20, 2026, 4:00 PM EST
22.28
-0.44 (-1.94%)
After-hours: Feb 20, 2026, 7:20 PM EST

Ultragenyx Pharmaceutical Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-569.18-606.64-707.42-454.03
Depreciation & Amortization
35.5426.0118.2213.24
Asset Writedown & Restructuring Costs
--75.03-
Loss (Gain) From Sale of Investments
-11.51-13.242248.67
Stock-Based Compensation
158.03135.23130.38104.95
Other Operating Activities
-40.99-1.0621.0911.71
Change in Accounts Receivable
-33.6-22.78-12.07-5.43
Change in Inventory
-11.21-6.93-9.7-3.12
Change in Accounts Payable
46.990.979.8532.31
Change in Unearned Revenue
----57.49
Change in Other Net Operating Assets
11.7315.333.8-29.51
Operating Cash Flow
-414.19-474.81-380.47-338.7
Capital Expenditures
-7.49-44.27-116.12-73.09
Cash Acquisitions
---75.03-
Sale (Purchase) of Intangibles
-12.5-2.5-30-
Investment in Securities
4.66219.82-69.66-121.34
Other Investing Activities
-2.44-5.05-0.84-0.94
Investing Cash Flow
-17.77168-291.65-195.37
Issuance of Common Stock
392.24388.1710.81119.04
Other Financing Activities
7-0.03490.4-0.49
Financing Cash Flow
399.24388.14501.21118.55
Foreign Exchange Rate Adjustments
-2.530.46-1.08-1.19
Net Cash Flow
-35.2481.8-171.98-416.71
Free Cash Flow
-421.68-519.07-496.59-411.79
Free Cash Flow Margin
-75.27%-119.53%-136.68%-117.18%
Free Cash Flow Per Share
-4.66-7.06-7.10-6.07
Levered Free Cash Flow
-207.49-312.21-370.58-244.82
Unlevered Free Cash Flow
-168.09-270.96-343.7-226.43
Change in Working Capital
13.92-15.160.24-63.24
Updated Feb 12, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q